Bioanalytical Systems reports rises in quarter three revenue

Bioanalytical Systems has reported a net income rise for quarter 3 of 2010

Bioanalytical Systems (BASi), a pharmaceutical development company, has reported revenues of $8.06m for the third quarter ended 30 June 2010 compared to $5.99m for the comparable period in 2009.

BASi has posted a net income of $288,000 for the third quarter 2010, or $0.06 per diluted share, compared to a net loss of $632,000, or $0.13 loss per diluted share, for the comparable period in 2009.

Operating income for the third quarter ended 30 June 2010 was $558,000, compared to operating loss of $571,000 for the comparable period in 2009.

For the nine months ended 30 June 2010, BASi has posted revenue of $21.38m compared to $23.26m for the year ago period.

For the nine months ended 30 June 2010, BASi has posted a net loss of $2.41m, or $0.49 loss per diluted share, compared to net loss of $4.05m, or $0.82 loss per diluted share, for the year ago period.

Operating loss for the nine months ended 30 June 2010 was $1.97m, compared to operating loss of $4.34m for the year ago period.

BASi is focused on providing contract research services and research instruments and supplies to the drug development companies and medical research organisations.

12 issues for £12